Last marrow standing: bone marrow transplantation for acquired bone marrow failure conditions.
Curr Hematol Malig Rep., Dec;7(4):292-9 (2012)
Correlation of clinical response and response duration with miR-145 induction by lenalidomide in CD34+ cells from patients with del(5q) myelodysplastic syndrome.
Haematologica., Aug (2012)
Five-group cytogenetic risk classification, monosomal karyotype, and outcome after hematopoietic cell transplantation for MDS or acute leukemia evolving from MDS.
Blood., Aug;120(7):1398-408 (2012)
Allogeneic hematopoietic cell transplantation in patients age 60-70 years with de novo high-risk myelodysplastic syndrome or secondary acute myelogenous leukemia: comparison with patients lacking donors who received azacitidine.
Biol. Blood Marrow Transplant., Sep;18(9):1415-21 (2012)
Pretransplantation therapy with azacitidine vs induction chemotherapy and posttransplantation outcome in patients with MDS.
Biol. Blood Marrow Transplant., Aug;18(8):1211-8 (2012)
The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation.
Blood., Mar;119(11):2657-64 (2012)
Allogeneic hematopoietic cell transplantation for chronic myelomonocytic leukemia: relapse-free survival is determined by karyotype and comorbidities.
Biol. Blood Marrow Transplant., Jun;17(6):908-15 (2011)
Conditioning with treosulfan and fludarabine followed by allogeneic hematopoietic cell transplantation for high-risk hematologic malignancies.
Biol. Blood Marrow Transplant., Mar;17(3):341-50 (2011)
Anti-thymocyte globulin plus etanercept as therapy for myelodysplastic syndromes (MDS): a phase II study.
Br. J. Haematol., Jun;149(5):706-10 (2010)
Myelodysplastic syndromes: emerging therapies, survival, and alternative outcomes.
Manag Care., Nov;18(11 Suppl 9):4-12; discussion 13-4 (2009)
Prolonged responses in patients with MDS and CMML treated with azacitidine and etanercept.
Br. J. Haematol., Mar;148(6):944-7 (2010)
Annu. Rev. Med., 61:345-58 (2010)
Clinical roundtable monograph. Combination therapies for MDS.
Clin Adv Hematol Oncol., Jul;7(7):S13-5 (2009)
Management of myelodysplastic syndromes: 2008 update.
Oncology (Williston Park, N.Y.)., Nov;22(12):1344-52 (2008)
Red blood cell transfusion dependence and outcome after allogeneic peripheral blood stem cell transplantation in patients with de novo myelodysplastic syndrome (MDS).
Biol. Blood Marrow Transplant., Nov;14(11):1217-25 (2008)
Validation of a flow cytometric scoring system as a prognostic indicator for posttransplantation outcome in patients with myelodysplastic syndrome.
Blood., Oct;112(7):2681-6 (2008)
Pretransplant neutropenia is associated with poor-risk cytogenetic features and increased infection-related mortality in patients with myelodysplastic syndromes.
Biol. Blood Marrow Transplant., Jul;14(7):799-806 (2008)
Reduced-intensity conditioning followed by allogeneic hematopoietic cell transplantation for adult patients with myelodysplastic syndrome and myeloproliferative disorders.
Biol. Blood Marrow Transplant., Feb;14(2):246-55 (2008)
Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation.
J. Clin. Oncol., Sep;25(27):4246-54 (2007)
Hematopoietic cell transplantation in patients with myelodysplastic syndrome or acute myeloid leukemia arising from myelodysplastic syndrome: similar outcomes in patients with de novo disease and disease following prior therapy or antecedent hematologic d
Blood., Aug;110(4):1379-87 (2007)
Hematopoietic cell transplantation as curative therapy for idiopathic myelofibrosis, advanced polycythemia vera, and essential thrombocythemia.
Biol. Blood Marrow Transplant., Mar;13(3):355-65 (2007)
Marrow fibrosis as a risk factor for posttransplantation outcome in patients with advanced myelodysplastic syndrome or acute myeloid leukemia with multilineage dysplasia.
Biol. Blood Marrow Transplant., Mar;13(3):345-54 (2007)
Outcomes with myeloid malignancies.
Hematology Am Soc Hematol Educ Program., 381-9 (2006)
Optimization of allogeneic transplant conditioning: not the time for dogma.
Leukemia., Oct;20(10):1701-5 (2006)
Reduced incidence of acute and chronic graft-versus-host disease with the addition of thymoglobulin to a targeted busulfan/cyclophosphamide regimen.
Biol. Blood Marrow Transplant., May;12(5):573-84 (2006)
Hemopoietic cell transplantation for the myelodysplastic syndromes.
Arch. Immunol. Ther. Exp. (Warsz.)., 53(4):297-307 (2005 Jul-Aug)
Pretransplantation induction chemotherapy and posttransplantation relapse in patients with advanced myelodysplastic syndrome.
Biol. Blood Marrow Transplant., Jan;11(1):65-73 (2005)